H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...

Exclusion Criteria

• •A subject will be excluded if one or more of the following conditions apply. Women Specific:
• •1. Breast-feeding or planning to become pregnant while participating in the study
• •Subject has received any of the following substances:
• •2. More than 10 days of systemic immunosuppressive medications or cytotoxic medications within the 4 weeks prior to enrollment or any within the 14 days prior to enrollment
• •3. Blood products within 16 weeks prior to enrollment
• •4. Live attenuated vaccines within 4 weeks prior to initial study vaccine administration
• •5. Investigational research agents within 4 weeks prior to enrollment or planning to receive investigational products while on the study
• •6. Medically indicated subunit or killed vaccines, e.g. influenza, pneumococcal within 2 weeks of initial study vaccine administration unless approved by the study Principal Investigator (PI)
• •7. Allergy treatment with antigen injections, unless on maintenance schedule
• •8. Current anti-TB prophylaxis or therapy
• •9. Previous H7 avian influenza investigational vaccine
• •Subject has a history of any of the following clinically significant conditions:
• •10. Contraindication to receiving an FDA-approved current seasonal influenza vaccination including hypersensitivity to eggs
• •11. Serious reactions to vaccines that preclude receipt of study vaccinations as determined by the investigator
• •12. Hereditary angioedema, acquired angioedema, or idiopathic forms of Angioedema
• •13. Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral or intravenous corticosteroids
• •14. Diabetes mellitus (type I or II), with the exception of gestational diabetes
• •15. Thyroid disease that is not well controlled
• •16. Idiopathic urticaria within the past year
• •17. Hypertension that is not well controlled
• •18. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
• •19. Malignancy that is active or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of the study
• •20. Seizure disorder other than: 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the last 3 years
• •21. Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen.
• •22. Type 1 hypersensitivity reaction to aminoglycoside antibiotics
• •23. Guillain-Barr(SqrRoot)(Copyright) Syndrome
• •24. Psychiatric condition that precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder; disorder requiring lithium; or within 5 years prior to enrollment, a history of suicide plan or attempt
• •25. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer s ability to give informed consent